Cargando…

Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors

BACKGROUND: Effective dose represents the potential risk to a population of stochastic effects of ionizing radiation (mainly lethal cancer). In recent years, there have been a number of revisions and updates influencing the way to estimate the effective dose. The aim of this work was to recalculate...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersson, Martin, Johansson, Lennart, Minarik, David, Leide-Svegborn, Sigrid, Mattsson, Sören
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545621/
https://www.ncbi.nlm.nih.gov/pubmed/26501451
http://dx.doi.org/10.1186/2197-7364-1-9
_version_ 1782386768015785984
author Andersson, Martin
Johansson, Lennart
Minarik, David
Leide-Svegborn, Sigrid
Mattsson, Sören
author_facet Andersson, Martin
Johansson, Lennart
Minarik, David
Leide-Svegborn, Sigrid
Mattsson, Sören
author_sort Andersson, Martin
collection PubMed
description BACKGROUND: Effective dose represents the potential risk to a population of stochastic effects of ionizing radiation (mainly lethal cancer). In recent years, there have been a number of revisions and updates influencing the way to estimate the effective dose. The aim of this work was to recalculate the effective dose values for the 338 different radiopharmaceuticals previously published by the International Commission on Radiological Protection (ICRP). METHOD: The new estimations are based on information on the cumulated activities per unit administered activity in various organs and tissues and for the various radiopharmaceuticals obtained from the ICRP publications 53, 80 and 106. The effective dose for adults was calculated using the new ICRP/International Commission on Radiation Units (ICRU) reference voxel phantoms and decay data from the ICRP publication 107. The ICRP human alimentary tract model has also been applied at the recalculations. The effective dose was calculated using the new tissue weighting factors from ICRP publications 103 and the prior factors from ICRP publication 60. The results of the new calculations were compared with the effective dose values published by the ICRP, which were generated with the Medical Internal Radiation Dose (MIRD) adult phantom and the tissue weighting factors from ICRP publication 60. RESULTS: For 79% of the radiopharmaceuticals, the new calculations gave a lower effective dose per unit administered activity than earlier estimated. As a mean for all radiopharmaceuticals, the effective dose was 25% lower. The use of the new adult computational voxel phantoms has a larger impact on the change of effective doses than the change to new tissue weighting factors. CONCLUSION: The use of the new computational voxel phantoms and the new weighting factors has generated new effective dose estimations. These are supposed to result in more realistic estimations of the radiation risk to a population undergoing nuclear medicine investigations than hitherto available values. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2197-7364-1-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4545621
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-45456212015-08-26 Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors Andersson, Martin Johansson, Lennart Minarik, David Leide-Svegborn, Sigrid Mattsson, Sören EJNMMI Phys Original Research BACKGROUND: Effective dose represents the potential risk to a population of stochastic effects of ionizing radiation (mainly lethal cancer). In recent years, there have been a number of revisions and updates influencing the way to estimate the effective dose. The aim of this work was to recalculate the effective dose values for the 338 different radiopharmaceuticals previously published by the International Commission on Radiological Protection (ICRP). METHOD: The new estimations are based on information on the cumulated activities per unit administered activity in various organs and tissues and for the various radiopharmaceuticals obtained from the ICRP publications 53, 80 and 106. The effective dose for adults was calculated using the new ICRP/International Commission on Radiation Units (ICRU) reference voxel phantoms and decay data from the ICRP publication 107. The ICRP human alimentary tract model has also been applied at the recalculations. The effective dose was calculated using the new tissue weighting factors from ICRP publications 103 and the prior factors from ICRP publication 60. The results of the new calculations were compared with the effective dose values published by the ICRP, which were generated with the Medical Internal Radiation Dose (MIRD) adult phantom and the tissue weighting factors from ICRP publication 60. RESULTS: For 79% of the radiopharmaceuticals, the new calculations gave a lower effective dose per unit administered activity than earlier estimated. As a mean for all radiopharmaceuticals, the effective dose was 25% lower. The use of the new adult computational voxel phantoms has a larger impact on the change of effective doses than the change to new tissue weighting factors. CONCLUSION: The use of the new computational voxel phantoms and the new weighting factors has generated new effective dose estimations. These are supposed to result in more realistic estimations of the radiation risk to a population undergoing nuclear medicine investigations than hitherto available values. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2197-7364-1-9) contains supplementary material, which is available to authorized users. Springer International Publishing 2014-09-29 /pmc/articles/PMC4545621/ /pubmed/26501451 http://dx.doi.org/10.1186/2197-7364-1-9 Text en © Andersson et al.; licensee Springer. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Original Research
Andersson, Martin
Johansson, Lennart
Minarik, David
Leide-Svegborn, Sigrid
Mattsson, Sören
Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors
title Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors
title_full Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors
title_fullStr Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors
title_full_unstemmed Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors
title_short Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors
title_sort effective dose to adult patients from 338 radiopharmaceuticals estimated using icrp biokinetic data, icrp/icru computational reference phantoms and icrp 2007 tissue weighting factors
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545621/
https://www.ncbi.nlm.nih.gov/pubmed/26501451
http://dx.doi.org/10.1186/2197-7364-1-9
work_keys_str_mv AT anderssonmartin effectivedosetoadultpatientsfrom338radiopharmaceuticalsestimatedusingicrpbiokineticdataicrpicrucomputationalreferencephantomsandicrp2007tissueweightingfactors
AT johanssonlennart effectivedosetoadultpatientsfrom338radiopharmaceuticalsestimatedusingicrpbiokineticdataicrpicrucomputationalreferencephantomsandicrp2007tissueweightingfactors
AT minarikdavid effectivedosetoadultpatientsfrom338radiopharmaceuticalsestimatedusingicrpbiokineticdataicrpicrucomputationalreferencephantomsandicrp2007tissueweightingfactors
AT leidesvegbornsigrid effectivedosetoadultpatientsfrom338radiopharmaceuticalsestimatedusingicrpbiokineticdataicrpicrucomputationalreferencephantomsandicrp2007tissueweightingfactors
AT mattssonsoren effectivedosetoadultpatientsfrom338radiopharmaceuticalsestimatedusingicrpbiokineticdataicrpicrucomputationalreferencephantomsandicrp2007tissueweightingfactors